Spinal-product specialist NuVasive (NUVA) got an upgrade and two price-target increases Wednesday after its Q2 earnings beat estimates late Tuesday. The stock hit a seven-year high in early trading. NuVasive’s profit rose 11% over the year-earlier quarter to 31 cents a share, beating analysts’ consensus by 6 cents, according to Thomson Reuters. Sales rose 6% to $202.9 million, about $2 million above estimates. NuVasive added 7 cents to its
Shares of spinal-products company NuVasive (NUVA) popped to a nearly four-year high on the stock market today, a day after the firm beat analysts’ Q4 profit expectations. In January, NuVasive had already given a preliminary sales number of $189 million, but the final number turned out to be $191 million, up 15% from the year-earlier quarter. Profit, which was not previously reported, rose 9% to 37 cents a share, beating analysts’ consensus by 5
Spinal-product company NuVasive (NUVA) beat Wall Street’s expectations as it released preliminary Q4 results and 2014 guidance Wednesday morning, sending NuVasive stock up 9% to a three-year high on the stock market today. The company said Q4 revenue was about $189 million, up 14% from the year-earlier quarter and $12 million above analysts’ consensus. It didn’t give a bottom-line number but said full-year operating margin would “exceed guidance”